KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Receivables - Net: 2017-2024

Historic Receivables - Net for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $7.3 million.

  • Aquestive Therapeutics' Receivables - Net rose 21.86% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 21.86%. This contributed to the annual value of $7.3 million for FY2024, which is 13.30% down from last year.
  • Per Aquestive Therapeutics' latest filing, its Receivables - Net stood at $7.3 million for FY2024, which was down 13.30% from $8.5 million recorded in FY2023.
  • Over the past 5 years, Aquestive Therapeutics' Receivables - Net peaked at $12.1 million during FY2021, and registered a low of $4.7 million during FY2022.
  • For the 3-year period, Aquestive Therapeutics' Receivables - Net averaged around $6.8 million, with its median value being $7.3 million (2024).
  • Its Receivables - Net has fluctuated over the past 5 years, first plummeted by 61.19% in 2022, then surged by 80.08% in 2023.
  • Aquestive Therapeutics' Receivables - Net (Yearly) stood at $7.0 million in 2020, then surged by 74.26% to $12.1 million in 2021, then crashed by 61.19% to $4.7 million in 2022, then surged by 80.08% to $8.5 million in 2023, then decreased by 13.30% to $7.3 million in 2024.